Faeth Therapeutics Clinical Trial Data
Faeth Therapeutics announced topline clinical data from its Phase 2 PIK-201 trial evaluating its product candidate PIKTOR in patients with advanced endometrial cancer. The trial evaluated PIKTOR (a combination of serabelisib and sapanisertib) in combination with paclitaxel. The company released a corporate presentation detailing these preliminary efficacy and safety results to investors.